Quanterix Corporation (QTRX)

The past six months have seen several events impacting Quanterix Corp.'s stock price. In Q4 2025, Quanterix reported a revenue increase but organic revenue declined, and the company reaffirmed its goal to achieve cash flow breakeven in the second half of 2026. Quanterix submitted a 510(k) premarket notification to the FDA for its multi-analyte algorithmic blood test for Alzheimer's disease. In Q1 2026, the company reported a revenue increase, but organic revenue declined, and the operating loss widened. Quanterix completed an $85 million annualized cost reduction plan and announced a collaboration with Tempus AI. The stock has experienced significant declines, trading near its 52-week low, and analysts have adjusted price targets downwards.

Demand for Quanterix Corp.'s products and services exhibits some seasonal and market-driven fluctuations. The first quarter typically experiences softness in academic and pharmaceutical markets and reduced U.S. federal research funding, which can lead to decreased demand for consumables and Accelerator Laboratory volumes. Management anticipates that Q2 revenues will be roughly in line to slightly ahead of Q1, with a stronger emphasis on commercial initiatives driving increased revenues in the second half of 2026. Commentary from Q4 2025 indicated pent-up demand from academic customers, which could contribute to a rebound in subsequent periods.

Quanterix Corp. is a life sciences company focused on ultra-sensitive biomarker detection, operating in the Healthcare sector, specifically in Healthcare Equipment & Supplies, Medical Devices, and Medical Specialties. The company's core business revolves around its Simoa technology, which enables the detection of protein biomarkers at extremely low concentrations. Major products and services include Simoa Technology, Instruments (HD-X, SR-X, and SP-X), Assay Kits, Laboratory Developed Tests (LDTs) & Assay Services, Custom Assay Development, and Consumables. Quanterix's technology is primarily applied in areas such as neurology, oncology, immunology, inflammation, cardiology, and infectious disease.

Quanterix Corp. has a global presence, operating in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company maintains direct sales and service operations in North America and several European countries, and its products and services are available globally through a network of distributor partners. Specific mentions of its operations or regulatory approvals include the Netherlands, Sweden, Hong Kong, China, and South Korea. The company's headquarters are located in Billerica, Massachusetts, USA.

Quanterix has cultivated a strong brand reputation as a leader in ultra-sensitive biomarker detection and a trusted partner in the scientific community. The company is recognized for fueling scientific discovery and transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics. Quanterix boasts approximately 6,300 peer-reviewed publications, underscoring its significant contributions to scientific research. The company's FDA 510(k) submission for a multi-analyte algorithmic blood test for Alzheimer's disease and its collaboration with Tempus AI highlight its commitment to addressing critical health challenges. The demonstration of the AidaBREAST™ multi-omic assay for early-stage invasive breast cancer further solidifies its reputation for innovative diagnostic solutions. The acquisition of Akoya Biosciences in 2025 has expanded its technological capabilities and market presence.

Institutional investors are the dominant force in Quanterix's ownership structure, holding a significant majority of shares, ranging from approximately 66.2% to 86.48%. Major institutional shareholders include Ameriprise Financial Inc., Portolan Capital Management, LLC, and BlackRock, Inc. Individual investors hold a smaller percentage, typically between 7% and 19% of the company's stock. Insider ownership was reported at 6.59% as of August 4, 2025.